Published on 24/12/2025
Conducting Multinational Clinical Trials in India: A Regulatory and Operational Roadmap
Introduction
India has become a key destination for multinational clinical trials (MCTs) due to its large and diverse patient population, experienced investigators, and competitive costs. The country’s participation in global studies enhances drug development timelines and allows data generation in an ethnically and genetically diverse population. However, conducting MCTs in India demands strict adherence to regulatory, ethical, and operational protocols as mandated by the Central Drugs Standard Control Organization (CDSCO) and governed by the New Drugs and Clinical Trials Rules (NDCTR), 2019.
For foreign sponsors, understanding India’s regulatory environment, approval timelines, and cultural nuances is critical to avoiding delays and ensuring compliance. This article offers a comprehensive overview of conducting multinational clinical trials in India, covering regulatory requirements, stakeholder responsibilities, and strategic considerations.
Background / Regulatory Framework
India’s clinical trial oversight is centrally managed by CDSCO, under the Ministry of Health and Family Welfare. Multinational trials require approval from the DCGI (Drugs Controller General of India) and local Ethics Committees. Since the implementation of NDCTR 2019, India has streamlined its approval process for MCTs, introducing timelines, clarity in responsibilities, and greater transparency.
Key Regulatory Elements
- NDCTR 2019 – Chapter
Core Clinical Trial Insights
1. Trial Authorization Process
- Sponsor/CRO must submit Form CT-04 through the SUGAM portal along with the protocol, Investigator’s Brochure (IB), informed consent forms, EC approvals, and insurance documentation.
- Approval timelines: NDCTR mandates a response within 90 days; often faster for life-threatening or orphan diseases.
- Subject Expert Committees (SECs) may be involved for protocol scientific assessment.
2. Ethics Committee Review and Coordination
- Each participating site must have EC approval from a CDSCO-registered committee.
- ECs review informed consent documents (including translations), risk-benefit analysis, and compensation arrangements.
- Central EC models may be used for multicentric trials with prior permission.
3. Import and Distribution of Investigational Product
Import license (Form CT-16) is required for bringing IP into India. IP storage, labeling, accountability, and return/destruction must comply with GCP and CDSCO conditions.
4. Sponsor Responsibilities
- Ensure local CRO partner is registered and trained in Indian GCP.
- Maintain trial insurance and SAE compensation mechanisms as per Schedule I of NDCTR.
- Submit periodic safety updates, annual reports, and protocol amendments to CDSCO and ECs.
- Ensure site readiness for inspection by CDSCO, US FDA, or other regulators.
5. Language and Consent Considerations
Informed Consent Forms (ICFs) must be translated into local languages and include all regulatory elements. AV recording is mandatory for new drug trials in India. Cultural sensitivity and community involvement improve recruitment and comprehension.
6. Site Selection and Investigator Readiness
- Select investigators with prior GCT experience and strong recruitment track records.
- Ensure availability of clinical trial infrastructure: pharmacy, archives, lab, documentation, and IT systems.
- GCP training records and CVs of all site staff must be maintained and available for inspection.
7. Safety Reporting Obligations
- SAEs: Report to CDSCO, EC, and sponsor within 24 hours; detailed report within 14 days.
- SAE causality and compensation assessment must be documented and traceable.
- Global expedited reports must include Indian cases in CIOMS format.
8. Data Acceptability and Global Submissions
Data generated in India is accepted by US FDA, EMA, PMDA, and WHO PQ provided the trials are compliant with GCP, ethical guidelines, and regulatory documentation is robust. Indian data is often essential in bridging studies for Asia-Pacific filings.
Best Practices & Preventive Measures
- Begin regulatory planning early; parallel EC and CDSCO submissions save time.
- Use bilingual consent forms and validated translations with back-translation checks.
- Set up robust monitoring and QA oversight mechanisms at Indian sites.
- Train investigators and staff on global trial protocols and SAE management.
- Conduct GCP and trial-specific training prior to site activation.
Scientific & Regulatory Evidence
- NDCTR 2019 – Chapter V: Governs multinational trial conduct.
- CDSCO Guidance on GCTs (2021): Submission format and timelines.
- ICMR National Ethical Guidelines: Ethical conduct of global trials in India.
- ICH E6(R2): GCP guidelines adopted in India.
Special Considerations
Rare Disease and Orphan Drug Trials: These receive fast-track review and may qualify for reduced documentation or priority meeting access.
Pediatric Multinational Studies: Require additional consent safeguards, EC oversight, and child-friendly materials approved by CDSCO.
Post-Approval Commitments: India may request post-marketing safety studies or additional data submissions after global trial completion.
When Sponsors Should Seek Regulatory Advice
- For global first-in-human or adaptive trial designs involving Indian sites
- When using non-traditional consent methods or decentralized components
- To understand alignment with EMA/FDA/PMDA expectations
- Before initiating orphan drug or priority indication trials
Sponsors can request formal pre-submission (Type B) meetings with CDSCO or written clarifications. Collaboration with local regulatory consultants is highly advised.
FAQs
1. Do multinational trials require separate Indian approval?
Yes. All trials involving Indian participants must be approved by CDSCO even if globally approved by US FDA or EMA.
2. How long does CDSCO approval take?
Up to 90 days under NDCTR. Timelines may be shorter for public health emergencies or orphan indications.
3. Is India data accepted in global submissions?
Yes, if trials follow ICH GCP and local compliance standards, data is accepted by global regulators.
4. Are foreign sponsors required to have an Indian legal representative?
Yes. Foreign sponsors must appoint an Indian representative or authorized CRO to act on their behalf.
5. Are multi-site trials allowed under a central EC?
Yes, with CDSCO permission, central EC approval may be accepted for multicentric trials.
Conclusion & Call-to-Action
India offers an attractive destination for multinational clinical trials due to its scientific capabilities, patient diversity, and evolving regulatory efficiency. However, success depends on careful planning, compliance with CDSCO and ICMR guidelines, and proactive engagement with local stakeholders. Sponsors must navigate the Indian regulatory landscape with precision to ensure ethical conduct, data credibility, and inspection readiness. For seamless global trial execution involving India, engage local regulatory experts and initiate early conversations with CDSCO and site ECs.